Il33 (interleukin 33) - Rat Genome Database

Send us a Message



 Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   
Search RGD Grant Resources Citing RGD About Us Contact Us
Genes Community Projects (beta) QTLs Strains Markers Genome Information Ontologies Cell Lines References Download Submit Data
OntoMate (Literature Search) JBrowse (Genome Browser) Synteny Browser (VCMap)  (beta) Variant Visualizer Multi-Ontology Enrichment (MOET) Gene-Ortholog Location Finder (GOLF) InterViewer (Protein-Protein Interactions) PhenoMiner (Quatitative Phenotypes) Gene Annotator OLGA (Gene List Generator) AllianceMine GViewer (Genome Viewer)
Aging & Age-Related Disease Cancer & Neoplastic Disease Cardiovascular Disease Coronavirus Disease Developmental Disease Diabetes Hematologic Disease Immune & Inflammatory Disease Infectious Disease Liver Disease Neurological Disease Obesity & Metabolic Syndrome Renal Disease Respiratory Disease Sensory Organ Disease
Find Models   new Genetic Models Autism Models Rat PhenoMiner (Quantitative Phenotypes) Chinchilla PhenoMiner Expected Ranges (Quantitative Phenotype) PhenoMiner Term Comparison Hybrid Rat Diversity Panel Phenotypes GERRC (Gene Editing Rat Resource Center) Phenotypes in Other Animal Models Animal Husbandry Strain Medical Records Phylogenetics Strain Availability Calendar Rats 101 Submissions Photo Archive
Pathways
Rat Community Forum Directory of Rat Laboratories Video Tutorials News RGD Publications RGD Presentations Archive Nomenclature Guidelines Resource Links Laboratory Resources Employment Resources
Gene: Il33 (interleukin 33) Rattus norvegicus
Analyze
Symbol: Il33
Name: interleukin 33
RGD ID: 1311155
Description: Predicted to enable cytokine activity and interleukin-33 receptor binding activity. Involved in cellular response to mechanical stimulus and positive regulation of oligodendrocyte differentiation. Predicted to be located in cytoplasm and nucleoplasm. Predicted to be active in extracellular space. Biomarker of acute myocardial infarction; colon cancer; and diabetes mellitus. Human ortholog(s) of this gene implicated in candidiasis; inflammatory bowel disease; and peptic ulcer disease. Orthologous to human IL33 (interleukin 33); PARTICIPATES IN influenza A pathway; INTERACTS WITH (+)-schisandrin B; 1-naphthyl isothiocyanate; 17beta-estradiol.
Type: protein-coding
RefSeq Status: VALIDATED
Previously known as: IL-33; interleukin-33; LOC361749; RGD1311155; similar to RIKEN cDNA 9230117N10
RGD Orthologs
Human
Mouse
Chinchilla
Bonobo
Dog
Squirrel
Pig
Green Monkey
Naked Mole-Rat
Alliance Genes
More Info more info ...
Latest Assembly: mRatBN7.2 - mRatBN7.2 Assembly
Position:
Rat AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
mRatBN7.21227,701,964 - 227,736,374 (+)NCBImRatBN7.2mRatBN7.2
mRatBN7.2 Ensembl1227,721,435 - 227,736,373 (+)EnsemblmRatBN7.2 Ensembl
UTH_Rnor_SHR_Utx1236,123,222 - 236,138,166 (+)NCBIRnor_SHRUTH_Rnor_SHR_Utx
UTH_Rnor_SHRSP_BbbUtx_1.01243,052,907 - 243,067,851 (+)NCBIRnor_SHRSPUTH_Rnor_SHRSP_BbbUtx_1.0
UTH_Rnor_WKY_Bbb_1.01235,869,667 - 235,884,579 (+)NCBIRnor_WKYUTH_Rnor_WKY_Bbb_1.0
Rnor_6.01248,112,611 - 248,147,030 (+)NCBIRnor6.0Rnor_6.0rn6Rnor6.0
Rnor_6.0 Ensembl1248,132,090 - 248,147,029 (+)EnsemblRnor6.0rn6Rnor6.0
Rnor_5.01255,382,760 - 255,397,661 (+)NCBIRnor5.0Rnor_5.0rn5Rnor5.0
RGSC_v3.41233,670,801 - 233,685,798 (+)NCBIRGSC3.4RGSC_v3.4rn4RGSC3.4
RGSC_v3.11233,834,823 - 233,849,820 (+)NCBI
Celera1224,871,607 - 224,886,518 (+)NCBICelera
Cytogenetic Map1q52NCBI
JBrowse: View Region in Genome Browser (JBrowse)
Model


Disease Annotations     Click to see Annotation Detail View
acute myocardial infarction  (IEP)
Alzheimer's disease  (ISS)
angiostrongyliasis  (ISO)
aortic atherosclerosis  (ISO)
asthma  (ISO)
atopic dermatitis  (ISO)
candidiasis  (ISO)
Cardiomegaly  (IDA,ISO)
Cardiovirus Infections  (ISO)
cerebral malaria  (ISO)
chromosome 9p deletion syndrome  (ISO)
Chronic Hepatitis B  (ISO)
chronic obstructive pulmonary disease  (ISO)
Chronic Periodontitis  (ISO)
clonorchiasis  (ISO)
Clostridium difficile colitis  (ISO)
colitis  (ISO)
colon cancer  (IEP)
common cold  (ISO)
cryptococcosis  (ISO)
dengue disease  (ISO)
diabetes mellitus  (IEP)
Experimental Arthritis  (ISO)
Experimental Colitis  (ISO)
Experimental Liver Cirrhosis  (ISO)
familial hemophagocytic lymphohistiocytosis 2  (ISO)
Fungal Lung Diseases  (ISO)
genetic disease  (ISO)
gout  (ISO)
Hantavirus hemorrhagic fever with renal syndrome  (ISO)
Helicobacter Infections  (ISO)
Hemolysis  (ISO)
herpes simplex  (ISO)
Hookworm Infections  (ISO)
Hyperalgesia  (IMP)
Immediate Hypersensitivity  (ISO)
inflammatory bowel disease  (ISO)
influenza  (ISO)
Intervertebral Disc Displacement  (IEP)
irritable bowel syndrome  (ISO)
kidney disease  (ISO)
listeriosis  (ISO)
liver cirrhosis  (ISO)
malaria  (ISO)
Nematode Infections  (ISO)
paracoccidioidomycosis  (ISO)
parasitic helminthiasis infectious disease  (ISO)
peptic ulcer disease  (ISO)
periodontitis  (ISO)
pleural tuberculosis  (ISO)
pneumocystosis  (ISO)
pneumonia  (ISO)
prostate cancer  (ISO)
Pseudomonas Infections  (ISO)
pulmonary edema  (ISO)
pulmonary tuberculosis  (ISO)
respiratory allergy  (ISO)
respiratory syncytial virus infectious disease  (ISO)
schistosomiasis  (ISO)
Schistosomiasis Japonica  (ISO)
Sepsis  (ISO)
Staphylococcal Pneumonia  (ISO)
Staphylococcal Skin Infections  (ISO)
Strongylida Infections  (ISO)
Superinfection  (ISO)
tongue squamous cell carcinoma  (ISO)
tuberculosis  (ISO)
ulcerative colitis  (ISO)
Viral Bronchiolitis  (ISO)
viral encephalitis  (ISO)
Viral Myocarditis  (ISO)

Gene-Chemical Interaction Annotations     Click to see Annotation Detail View
(+)-schisandrin B  (EXP)
(S)-nicotine  (ISO)
1,1,1-trichloro-2,2-bis(4-hydroxyphenyl)ethane  (ISO)
1-naphthyl isothiocyanate  (EXP)
17beta-estradiol  (EXP,ISO)
2,2',4,4',5,5'-hexachlorobiphenyl  (EXP)
2,3,7,8-tetrachlorodibenzodioxine  (EXP,ISO)
2,3-bis(4-hydroxyphenyl)propionitrile  (ISO)
2-acetamidofluorene  (ISO)
2-amino-2-deoxy-D-glucopyranose  (EXP)
2-hydroxypropanoic acid  (ISO)
3,3',4,4',5-pentachlorobiphenyl  (EXP,ISO)
3-chloropropane-1,2-diol  (EXP)
3H-1,2-dithiole-3-thione  (EXP)
4,4'-diaminodiphenylmethane  (EXP)
4,4'-sulfonyldiphenol  (ISO)
4-hydroxyphenyl retinamide  (ISO)
6-propyl-2-thiouracil  (EXP)
7,12-dimethyltetraphene  (EXP,ISO)
acetamide  (EXP)
acetic acid  (ISO)
acrylamide  (EXP)
aflatoxin B1  (ISO)
aldehydo-D-glucosamine  (EXP)
all-trans-retinoic acid  (ISO)
AM-251  (EXP)
amiodarone  (EXP)
amitriptyline  (EXP)
antirheumatic drug  (ISO)
Aroclor 1254  (EXP)
atrazine  (EXP)
avobenzone  (ISO)
benzo[a]pyrene  (ISO)
beta-D-glucosamine  (EXP)
bis(2-chloroethyl) sulfide  (EXP)
bisphenol A  (EXP,ISO)
bisphenol F  (ISO)
bleomycin A2  (ISO)
C60 fullerene  (EXP)
cadmium atom  (ISO)
cadmium dichloride  (EXP,ISO)
cadmium sulfate  (ISO)
calcitriol  (ISO)
calycosin  (EXP)
carbon monoxide  (EXP)
carbon nanotube  (ISO)
chloroprene  (ISO)
chlorpyrifos  (ISO)
chromium(6+)  (ISO)
cisplatin  (ISO)
clomipramine  (EXP)
copper atom  (EXP,ISO)
copper(0)  (EXP,ISO)
crocidolite asbestos  (ISO)
deoxynivalenol  (ISO)
dexamethasone  (ISO)
diclofenac  (ISO)
dimethylarsinic acid  (EXP)
dioxygen  (EXP)
diuron  (EXP,ISO)
doxorubicin  (ISO)
endosulfan  (EXP)
epoxiconazole  (ISO)
ethanol  (EXP,ISO)
ferric oxide  (ISO)
ferulic acid  (ISO)
flutamide  (EXP)
folic acid  (ISO)
formaldehyde  (ISO)
fragrance  (ISO)
furan  (EXP)
genistein  (ISO)
glutathione  (EXP)
glyphosate  (ISO)
graphene oxide  (ISO)
hydroquinone  (ISO)
imipramine  (EXP)
imiquimod  (ISO)
indole-3-methanol  (EXP)
irinotecan  (ISO)
ketoconazole  (EXP)
leflunomide  (EXP)
lidocaine  (EXP)
lipopolysaccharide  (ISO)
luteolin  (ISO)
lysophosphatidylcholine  (ISO)
mechlorethamine  (ISO)
mercury atom  (ISO)
mercury(0)  (ISO)
metformin  (EXP)
methoxychlor  (ISO)
microcystin-LR  (ISO)
Muraglitazar  (EXP)
N-acetyl-L-cysteine  (ISO)
N-nitrosodiethylamine  (ISO)
N-nitrosodimethylamine  (EXP)
N-nitrosomorpholine  (EXP)
nefazodone  (EXP)
nickel atom  (ISO)
nicotine  (ISO)
orphenadrine  (EXP)
oxaliplatin  (EXP)
ozone  (ISO)
paracetamol  (EXP,ISO)
paraquat  (ISO)
pemetrexed  (ISO)
pentanal  (ISO)
pentane-2,3-dione  (EXP,ISO)
perfluorooctane-1-sulfonic acid  (ISO)
perfluorooctanoic acid  (EXP)
phenformin  (EXP)
phenobarbital  (EXP)
phorbol 13-acetate 12-myristate  (ISO)
phosgene  (EXP)
pirinixic acid  (EXP,ISO)
poly(I:C)  (ISO)
potassium dichromate  (ISO)
pregnenolone 16alpha-carbonitrile  (EXP)
progesterone  (EXP,ISO)
quartz  (ISO)
quinazolines  (ISO)
rac-lactic acid  (ISO)
S-(1,2-dichlorovinyl)-L-cysteine  (ISO)
silicon dioxide  (ISO)
sodium dichromate  (EXP,ISO)
sodium dodecyl sulfate  (ISO)
staurosporine  (ISO)
streptozocin  (EXP)
sulforaphane  (ISO)
Tesaglitazar  (EXP)
tetrachloromethane  (EXP,ISO)
thioacetamide  (EXP)
titanium dioxide  (ISO)
toluene  (EXP)
toluene 2,4-diisocyanate  (ISO)
topotecan  (EXP)
tremolite asbestos  (ISO)
trichloroethene  (EXP)
triclosan  (ISO)
trimellitic anhydride  (ISO)
triptonide  (ISO)
troglitazone  (EXP)
valproic acid  (ISO)
vinclozolin  (EXP)
Vinpocetine  (ISO)
WIN 55212-2  (EXP)
zaragozic acid A  (EXP,ISO)

Gene Ontology Annotations     Click to see Annotation Detail View

Biological Process
cellular response to mechanical stimulus  (IEP)
defense response to virus  (IEA,ISO)
extrinsic apoptotic signaling pathway  (IEA,ISO)
gene expression  (IEA,ISO)
interleukin-33-mediated signaling pathway  (IEA,ISO)
macrophage activation involved in immune response  (ISO)
macrophage differentiation  (IEA,ISO,ISS)
microglial cell activation involved in immune response  (IEA,ISO)
microglial cell proliferation  (IEA,ISO)
negative regulation of immunoglobulin production  (IEA,ISO)
negative regulation of inflammatory response to wounding  (IEA,ISO)
negative regulation of leukocyte migration  (IEA,ISO)
negative regulation of macrophage proliferation  (IEA,ISO)
negative regulation of T-helper 1 type immune response  (IEA,ISO)
negative regulation of transcription by RNA polymerase II  (IEA,ISO)
negative regulation of type II interferon production  (IEA,ISO)
positive regulation of CD80 production  (IEA,ISO)
positive regulation of CD86 production  (IEA,ISO)
positive regulation of cellular defense response  (IEA,ISO)
positive regulation of chemokine production  (IEA,ISO)
positive regulation of cytokine production  (IBA)
positive regulation of gene expression  (ISO)
positive regulation of immunoglobulin production  (IEA,ISO)
positive regulation of inflammatory response  (IBA,IEA,ISO)
positive regulation of interleukin-13 production  (IEA,ISO)
positive regulation of interleukin-4 production  (IEA,ISO)
positive regulation of interleukin-5 production  (IEA,ISO)
positive regulation of interleukin-6 production  (IEA,ISO)
positive regulation of macrophage activation  (IEA,ISO)
positive regulation of MHC class I biosynthetic process  (IEA,ISO)
positive regulation of MHC class II biosynthetic process  (IEA,ISO)
positive regulation of nitric-oxide synthase biosynthetic process  (IEA,ISO)
positive regulation of oligodendrocyte differentiation  (IMP)
positive regulation of proteasomal ubiquitin-dependent protein catabolic process  (IEA,ISO)
positive regulation of transcription by RNA polymerase II  (IEA,ISO)
positive regulation of tumor necrosis factor production  (IEA,ISO)
positive regulation of type 2 immune response  (IEA,ISO)
protein import into nucleus  (IEA,ISO)
signal transduction  (IEA)
type 2 immune response  (IEA,ISO)

Cellular Component

Molecular Function

Molecular Pathway Annotations     Click to see Annotation Detail View
References

References - curated
# Reference Title Reference Citation
1. Differential production of interleukin-1 family cytokines (IL-1β, IL-18, IL-33 and IL-37) in patients with paracoccidioidomycosis: correlation with clinical form and antifungal therapy. Alves ABRM, etal., Med Mycol. 2018 Apr 1;56(3):332-343. doi: 10.1093/mmy/myx050.
2. A potential role for interleukin-33 and gamma-epithelium sodium channel in the pathogenesis of human malaria associated lung injury. Ampawong S, etal., Malar J. 2015 Oct 5;14:389. doi: 10.1186/s12936-015-0922-x.
3. New Host-Directed Therapeutics for the Treatment of Clostridioides difficile Infection. Andersson JA, etal., mBio. 2020 Mar 10;11(2). pii: mBio.00053-20. doi: 10.1128/mBio.00053-20.
4. The Alarmin IL-33 Derived from HSV-2-Infected Keratinocytes Triggers Mast Cell-Mediated Antiviral Innate Immunity. Aoki R, etal., J Invest Dermatol. 2016 Jun;136(6):1290-1292. doi: 10.1016/j.jid.2016.01.030. Epub 2016 Feb 9.
5. Decreased circulating interleukin-33 concentration in Helicobacter pylori-infected patients with peptic ulcer: Evaluation of its association with a cytokine gene polymorphism, gender of patients and bacterial virulence factor CagA. Bassagh A, etal., Microb Pathog. 2019 Nov;136:103708. doi: 10.1016/j.micpath.2019.103708. Epub 2019 Sep 3.
6. IL-33-mediated protection against experimental cerebral malaria is linked to induction of type 2 innate lymphoid cells, M2 macrophages and regulatory T cells. Besnard AG, etal., PLoS Pathog. 2015 Feb 6;11(2):e1004607. doi: 10.1371/journal.ppat.1004607. eCollection 2015 Feb.
7. Liver-resident macrophage necroptosis orchestrates type 1 microbicidal inflammation and type-2-mediated tissue repair during bacterial infection. Blériot C, etal., Immunity. 2015 Jan 20;42(1):145-58. doi: 10.1016/j.immuni.2014.12.020. Epub 2014 Dec 25.
8. ILC2s and T cells cooperate to ensure maintenance of M2 macrophages for lung immunity against hookworms. Bouchery T, etal., Nat Commun. 2015 Apr 27;6:6970. doi: 10.1038/ncomms7970.
9. Helminth-derived molecules inhibit colitis-associated colon cancer development through NF-κB and STAT3 regulation. Callejas BE, etal., Int J Cancer. 2019 Dec 1;145(11):3126-3139. doi: 10.1002/ijc.32626. Epub 2019 Aug 30.
10. Pediatric severe asthma with fungal sensitization is mediated by steroid-resistant IL-33. Castanhinha S, etal., J Allergy Clin Immunol. 2015 Aug;136(2):312-22.e7. doi: 10.1016/j.jaci.2015.01.016. Epub 2015 Mar 5.
11. [Changes in plasma interleukin-33 concentration in sepsis and its correlation with seriousness of sepsis]. Chang D, etal., Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2015 Feb;27(2):138-42. doi: 10.3760/cma.j.issn.2095-4352.2015.02.012.
12. [Correlation between acute schistosomiasis japonica and serum interleukin-33 levels]. Chen RQ, etal., Zhongguo Xue Xi Chong Bing Fang Zhi Za Zhi. 2012 Feb;24(1):32-4, 39.
13. Group 2 Innate Lymphoid Cells (ILC2s) Are Key Mediators of the Inflammatory Response in Polymicrobial Sepsis. Chun TT, etal., Am J Pathol. 2018 Sep;188(9):2097-2108. doi: 10.1016/j.ajpath.2018.05.009. Epub 2018 Jun 20.
14. Arginase-1 and Treg Profile Appear to Modulate Inflammatory Process in Patients with Chronic Gastritis: IL-33 May Be the Alarm Cytokine in H. pylori-Positive Patients. da Silva EAW, etal., Mediators Inflamm. 2019 Jun 20;2019:2536781. doi: 10.1155/2019/2536781. eCollection 2019.
15. IL-33 mediates the expressions of IL-5 and IL-13 in Angiostrongylus cantonensis-infected mice. Du WY, etal., Exp Parasitol. 2013 Nov;135(3):587-94. doi: 10.1016/j.exppara.2013.09.012. Epub 2013 Sep 27.
16. IL-33 signaling is essential to attenuate viral-induced encephalitis development by downregulating iNOS expression in the central nervous system. Franca RF, etal., J Neuroinflammation. 2016 Jun 22;13(1):159. doi: 10.1186/s12974-016-0628-1.
17. Thymic stromal lymphopoietin, IL-33, and periostin in hospitalized infants with viral bronchiolitis. García-García ML, etal., Medicine (Baltimore). 2017 May;96(18):e6787. doi: 10.1097/MD.0000000000006787.
18. Phylogenetic-based propagation of functional annotations within the Gene Ontology consortium. Gaudet P, etal., Brief Bioinform. 2011 Sep;12(5):449-62. doi: 10.1093/bib/bbr042. Epub 2011 Aug 27.
19. Rhinovirus-induces progression of lung disease in a mouse model of COPD via IL-33/ST2 signaling axis. Gimenes JA, etal., Clin Sci (Lond). 2019 Apr 29;133(8):983-996. doi: 10.1042/CS20181088. Print 2019 Apr 30.
20. Group 2 innate lymphoid cells exhibit progressively higher levels of activation during worsening of liver fibrosis. Gonzalez-Polo V, etal., Ann Hepatol. 2019 Mar - Apr;18(2):366-372. doi: 10.1016/j.aohep.2018.12.001. Epub 2019 Apr 25.
21. NFATc1-E2F1-LMCD1-Mediated IL-33 Expression by Thrombin Is Required for Injury-Induced Neointima Formation. Govatati S, etal., Arterioscler Thromb Vasc Biol. 2019 Jun;39(6):1212-1226. doi: 10.1161/ATVBAHA.119.312729.
22. Natural helper cells mediate respiratory syncytial virus-induced airway inflammation by producing type 2 cytokines in an IL-33-dependent manner. Han X, etal., Immunotherapy. 2017 Aug;9(9):715-722. doi: 10.2217/imt-2017-0037. Epub 2017 Aug 3.
23. Down-regulation of microRNA-203-3p initiates type 2 pathology during schistosome infection via elevation of interleukin-33. He X, etal., PLoS Pathog. 2018 Mar 19;14(3):e1006957. doi: 10.1371/journal.ppat.1006957. eCollection 2018 Mar.
24. Lung epithelium is the major source of IL-33 and is regulated by IL-33-dependent and IL-33-independent mechanisms in pulmonary cryptococcosis. Heyen L, etal., Pathog Dis. 2016 Oct;74(7). pii: ftw086. doi: 10.1093/femspd/ftw086. Epub 2016 Sep 4.
25. Relevance of serum interleukin-33 and ST2 levels and the natural course of chronic hepatitis B virus infection. Huan SL, etal., BMC Infect Dis. 2016 May 16;16:200. doi: 10.1186/s12879-016-1543-x.
26. IL-33/ST2 signaling contributes to radicular pain by modulating MAPK and NF-κB activation and inflammatory mediator expression in the spinal cord in rat models of noncompressive lumber disk herniation. Huang SJ, etal., J Neuroinflammation. 2018 Jan 12;15(1):12. doi: 10.1186/s12974-017-1021-4.
27. Induction of IL-33 expression and activity in central nervous system glia. Hudson CA, etal., J Leukoc Biol. 2008 Sep;84(3):631-43. doi: 10.1189/jlb.1207830. Epub 2008 Jun 13.
28. Expression of interleukin-33 is correlated with poor prognosis of patients with squamous cell carcinoma of the tongue. Ishikawa K, etal., Auris Nasus Larynx. 2014 Dec;41(6):552-7. doi: 10.1016/j.anl.2014.08.007. Epub 2014 Sep 2.
29. IL-33 delivery induces serous cavity macrophage proliferation independent of interleukin-4 receptor alpha. Jackson-Jones LH, etal., Eur J Immunol. 2016 Oct;46(10):2311-2321. doi: 10.1002/eji.201646442.
30. IL-33 priming regulates multiple steps of the neutrophil-mediated anti-Candida albicans response by modulating TLR and dectin-1 signals. Le HT, etal., J Immunol. 2012 Jul 1;189(1):287-95. doi: 10.4049/jimmunol.1103564. Epub 2012 Jun 1.
31. Association between elevated pleural interleukin-33 levels and tuberculous pleurisy. Lee KS, etal., Ann Lab Med. 2013 Jan;33(1):45-51. doi: 10.3343/alm.2013.33.1.45. Epub 2012 Dec 17.
32. Combined detections of interleukin-33 and adenosine deaminase for diagnosis of tuberculous pleural effusion. Li D, etal., Int J Clin Exp Pathol. 2015 Jan 1;8(1):888-93. eCollection 2015.
33. Contribution of tissue transglutaminase to the severity of hepatic fibrosis resulting from Schistosoma japonicum infection through the regulation of IL-33/ST2 expression. Li ZY, etal., Parasit Vectors. 2019 Jun 14;12(1):302. doi: 10.1186/s13071-019-3542-4.
34. Natural helper cells contribute to pulmonary eosinophilia by producing IL-13 via IL-33/ST2 pathway in a murine model of respiratory syncytial virus infection. Liu J, etal., Int Immunopharmacol. 2015 Sep;28(1):337-43. doi: 10.1016/j.intimp.2015.05.035. Epub 2015 Jun 1.
35. Virus-like particles presenting interleukin-33 molecules: immunization characteristics and potentials of blockingIL-33/ST2 pathway in allergic airway inflammation. Long Q, etal., Hum Vaccin Immunother. 2014;10(8):2303-11. doi: 10.4161/hv.29425.
36. IL-33 Exacerbates Periodontal Disease through Induction of RANKL. Malcolm J, etal., J Dent Res. 2015 Jul;94(7):968-75. doi: 10.1177/0022034515577815. Epub 2015 Mar 25.
37. Interleukin-33 contributes to disease severity in Dengue virus infection in mice. Marques RE, etal., Immunology. 2018 Dec;155(4):477-490. doi: 10.1111/imm.12988. Epub 2018 Sep 10.
38. The effect of diabetes on ovaries in a rat model: the role of interleukin-33 and apoptosis. Nayki C, etal., Gynecol Endocrinol. 2017 Sep;33(9):708-711. doi: 10.1080/09513590.2017.1313971. Epub 2017 Apr 17.
39. IL-33 and M2a alveolar macrophages promote lung defense against the atypical fungal pathogen Pneumocystis murina. Nelson MP, etal., J Immunol. 2011 Feb 15;186(4):2372-81. doi: 10.4049/jimmunol.1002558. Epub 2011 Jan 10.
40. Critical role of IL-33 receptor ST2 in experimental cerebral malaria development. Palomo J, etal., Eur J Immunol. 2015 May;45(5):1354-65. doi: 10.1002/eji.201445206. Epub 2015 Mar 20.
41. Interleukin 33 mediates type 2 immunity and inflammation in the central nervous system of mice infected with Angiostrongylus cantonensis. Peng H, etal., J Infect Dis. 2013 Mar 1;207(5):860-9. doi: 10.1093/infdis/jis682. Epub 2012 Nov 12.
42. KEGG Annotation Import Pipeline Pipeline to import KEGG annotations from KEGG into RGD
43. M2 macrophages or IL-33 treatment attenuate ongoing Mycobacterium tuberculosis infection. Piñeros AR, etal., Sci Rep. 2017 Jan 27;7:41240. doi: 10.1038/srep41240.
44. GOA pipeline RGD automated data pipeline
45. ClinVar Automated Import and Annotation Pipeline RGD automated import pipeline for ClinVar variants, variant-to-disease annotations and gene-to-disease annotations
46. Data Import for Chemical-Gene Interactions RGD automated import pipeline for gene-chemical interactions
47. Novel protective mechanism for interleukin-33 at the mucosal barrier during influenza-associated bacterial superinfection. Robinson KM, etal., Mucosal Immunol. 2018 Jan;11(1):199-208. doi: 10.1038/mi.2017.32. Epub 2017 Apr 12.
48. ST2 contributes to T-cell hyperactivation and fatal hemophagocytic lymphohistiocytosis in mice. Rood JE, etal., Blood. 2016 Jan 28;127(4):426-35. doi: 10.1182/blood-2015-07-659813. Epub 2015 Oct 30.
49. IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system. Sanada S, etal., J Clin Invest. 2007 Jun;117(6):1538-49. doi: 10.1172/JCI30634. Epub 2007 May 10.
50. IL-10-producing regulatory B cells induced by IL-33 (Breg(IL-33)) effectively attenuate mucosal inflammatory responses in the gut. Sattler S, etal., J Autoimmun. 2014 May;50:107-22. doi: 10.1016/j.jaut.2014.01.032. Epub 2014 Feb 1.
51. Neutralisation of the interleukin-33/ST2 pathway ameliorates experimental colitis through enhancement of mucosal healing in mice. Sedhom MA, etal., Gut. 2013 Dec;62(12):1714-23. doi: 10.1136/gutjnl-2011-301785. Epub 2012 Nov 21.
52. IL-33 promotes GATA-3 polarization of gut-derived T cells in experimental and ulcerative colitis. Seidelin JB, etal., J Gastroenterol. 2015 Feb;50(2):180-90. doi: 10.1007/s00535-014-0982-7. Epub 2014 Aug 12.
53. IL-33/ST2 contributes to severe symptoms in Plasmodium chabaudi-infected BALB/c mice. Seki T, etal., Parasitol Int. 2018 Feb;67(1):64-69. doi: 10.1016/j.parint.2017.03.008. Epub 2017 Mar 27.
54. IL-33 Ameliorates the Development of MSU-Induced Inflammation Through Expanding MDSCs-Like Cells. Shang K, etal., Front Endocrinol (Lausanne). 2019 Feb 26;10:36. doi: 10.3389/fendo.2019.00036. eCollection 2019.
55. Inflammatory bowel disease-associated interleukin-33 is preferentially expressed in ulceration-associated myofibroblasts. Sponheim J, etal., Am J Pathol. 2010 Dec;177(6):2804-15. doi: 10.2353/ajpath.2010.100378. Epub 2010 Oct 29.
56. Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences. Strausberg RL, etal., Proc Natl Acad Sci U S A. 2002 Dec 24;99(26):16899-903. Epub 2002 Dec 11.
57. Down-regulation of interleukin-33 expression in oligodendrocyte precursor cells impairs oligodendrocyte lineage progression. Sung HY, etal., J Neurochem. 2019 Sep;150(6):691-708. doi: 10.1111/jnc.14788. Epub 2019 Jul 10.
58. Modulation of IL-33/ST2 system in postinfarction heart failure: correlation with cardiac remodelling markers. Sánchez-Más J, etal., Eur J Clin Invest. 2014 Jul;44(7):643-51. doi: 10.1111/eci.12282.
59. IL-33-induced alternatively activated macrophage attenuates the development of TNBS-induced colitis. Tu L, etal., Oncotarget. 2017 Apr 25;8(17):27704-27714. doi: 10.18632/oncotarget.15984.
60. IL-33 enhances macrophage M2 polarization and protects mice from CVB3-induced viral myocarditis. Wang C, etal., J Mol Cell Cardiol. 2017 Feb;103:22-30. doi: 10.1016/j.yjmcc.2016.12.010. Epub 2016 Dec 29.
61. Red Blood Cells Store and Release Interleukin-33. Wei J, etal., J Investig Med. 2015 Aug;63(6):806-10. doi: 10.1097/JIM.0000000000000213.
62. Chronic IL-33 expression predisposes to virus-induced asthma exacerbations by increasing type 2 inflammation and dampening antiviral immunity. Werder RB, etal., J Allergy Clin Immunol. 2018 May;141(5):1607-1619.e9. doi: 10.1016/j.jaci.2017.07.051. Epub 2017 Sep 22.
63. Trefoil factor 2 rapidly induces interleukin 33 to promote type 2 immunity during allergic asthma and hookworm infection. Wills-Karp M, etal., J Exp Med. 2012 Mar 12;209(3):607-22. doi: 10.1084/jem.20110079. Epub 2012 Feb 13.
64. Interleukin-33 contributes to ILC2 activation and early inflammation-associated lung injury during abdominal sepsis. Xu H, etal., Immunol Cell Biol. 2018 Oct;96(9):935-947. doi: 10.1111/imcb.12159. Epub 2018 May 17.
65. Contribution of IL-33-activated type II innate lymphoid cells to pulmonary eosinophilia in intestinal nematode-infected mice. Yasuda K, etal., Proc Natl Acad Sci U S A. 2012 Feb 28;109(9):3451-6. doi: 10.1073/pnas.1201042109. Epub 2012 Feb 13.
66. IL-33 promotes Staphylococcus aureus-infected wound healing in mice. Yin H, etal., Int Immunopharmacol. 2013 Oct;17(2):432-8. doi: 10.1016/j.intimp.2013.07.008. Epub 2013 Jul 25.
67. Expression and potential roles of IL-33/ST2 in the immune regulation during Clonorchis sinensis infection. Yu Q, etal., Parasitol Res. 2016 Jun;115(6):2299-305. doi: 10.1007/s00436-016-4974-9. Epub 2016 Mar 5.
68. Interleukin-33 promotes Th2 immune responses in infected mice with Schistosoma japonicum. Yu Y, etal., Parasitol Res. 2015 Aug;114(8):2911-8. doi: 10.1007/s00436-015-4492-1. Epub 2015 May 6.
69. Baicalin may alleviate inflammatory infiltration in dextran sodium sulfate-induced chronic ulcerative colitis via inhibiting IL-33 expression. Zhang CL, etal., Life Sci. 2017 Oct 1;186:125-132. doi: 10.1016/j.lfs.2017.08.010. Epub 2017 Aug 9.
70. IL-33/ST2 correlates with severity of haemorrhagic fever with renal syndrome and regulates the inflammatory response in Hantaan virus-infected endothelial cells. Zhang Y, etal., PLoS Negl Trop Dis. 2015 Feb 6;9(2):e0003514. doi: 10.1371/journal.pntd.0003514. eCollection 2015 Feb.
71. IL-33 Enhances Humoral Immunity Against Chronic HBV Infection Through Activating CD4(+)CXCR5(+) TFH Cells. Zhao PW, etal., J Interferon Cytokine Res. 2015 Jun;35(6):454-63. doi: 10.1089/jir.2013.0122. Epub 2015 Feb 25.
Additional References at PubMed
PMID:15489334   PMID:17185418   PMID:17623648   PMID:18268038   PMID:18787100   PMID:18836528   PMID:19666510   PMID:19841166   PMID:19919994   PMID:20689058   PMID:21349253   PMID:21357533  
PMID:21494550   PMID:22215666   PMID:22660580   PMID:23219998   PMID:23418608   PMID:23446743   PMID:23630360   PMID:24327583   PMID:25417195   PMID:25458175   PMID:25815839   PMID:26571038  
PMID:26927343   PMID:27022724   PMID:27055881   PMID:28274612   PMID:29045903   PMID:29508184   PMID:30410547   PMID:31034519   PMID:31726037   PMID:32298206   PMID:32513089   PMID:32592632  
PMID:33423320   PMID:34225736   PMID:35452731   PMID:36110250   PMID:36768322  


Genomics

Comparative Map Data
Il33
(Rattus norvegicus - Norway rat)
Rat AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
mRatBN7.21227,701,964 - 227,736,374 (+)NCBImRatBN7.2mRatBN7.2
mRatBN7.2 Ensembl1227,721,435 - 227,736,373 (+)EnsemblmRatBN7.2 Ensembl
UTH_Rnor_SHR_Utx1236,123,222 - 236,138,166 (+)NCBIRnor_SHRUTH_Rnor_SHR_Utx
UTH_Rnor_SHRSP_BbbUtx_1.01243,052,907 - 243,067,851 (+)NCBIRnor_SHRSPUTH_Rnor_SHRSP_BbbUtx_1.0
UTH_Rnor_WKY_Bbb_1.01235,869,667 - 235,884,579 (+)NCBIRnor_WKYUTH_Rnor_WKY_Bbb_1.0
Rnor_6.01248,112,611 - 248,147,030 (+)NCBIRnor6.0Rnor_6.0rn6Rnor6.0
Rnor_6.0 Ensembl1248,132,090 - 248,147,029 (+)EnsemblRnor6.0rn6Rnor6.0
Rnor_5.01255,382,760 - 255,397,661 (+)NCBIRnor5.0Rnor_5.0rn5Rnor5.0
RGSC_v3.41233,670,801 - 233,685,798 (+)NCBIRGSC3.4RGSC_v3.4rn4RGSC3.4
RGSC_v3.11233,834,823 - 233,849,820 (+)NCBI
Celera1224,871,607 - 224,886,518 (+)NCBICelera
Cytogenetic Map1q52NCBI
IL33
(Homo sapiens - human)
Human AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
GRCh3896,215,149 - 6,257,983 (+)NCBIGRCh38GRCh38hg38GRCh38
GRCh38.p14 Ensembl96,215,786 - 6,257,983 (+)EnsemblGRCh38hg38GRCh38
GRCh3796,215,149 - 6,257,983 (+)NCBIGRCh37GRCh37hg19GRCh37
Build 3696,231,678 - 6,247,982 (+)NCBINCBI36Build 36hg18NCBI36
Build 3496,231,677 - 6,247,982NCBI
Celera96,179,137 - 6,195,439 (+)NCBICelera
Cytogenetic Map9p24.1NCBI
HuRef96,171,374 - 6,213,493 (+)NCBIHuRef
CHM1_196,216,394 - 6,258,768 (+)NCBICHM1_1
T2T-CHM13v2.096,220,289 - 6,263,045 (+)NCBIT2T-CHM13v2.0
Il33
(Mus musculus - house mouse)
Mouse AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
GRCm391929,902,513 - 29,938,118 (+)NCBIGRCm39GRCm39mm39
GRCm39 Ensembl1929,902,514 - 29,938,118 (+)EnsemblGRCm39 Ensembl
GRCm381929,925,113 - 29,960,718 (+)NCBIGRCm38GRCm38mm10GRCm38
GRCm38.p6 Ensembl1929,925,114 - 29,960,718 (+)EnsemblGRCm38mm10GRCm38
MGSCv371929,999,604 - 30,035,205 (+)NCBIGRCm37MGSCv37mm9NCBIm37
MGSCv361930,015,647 - 30,026,715 (+)NCBIMGSCv36mm8
Celera1930,700,532 - 30,736,141 (+)NCBICelera
Cytogenetic Map19C1NCBI
cM Map1924.56NCBI
Il33
(Chinchilla lanigera - long-tailed chinchilla)
Chinchilla AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
ChiLan1.0 EnsemblNW_00495543410,171,812 - 10,188,948 (+)EnsemblChiLan1.0
ChiLan1.0NW_00495543410,145,449 - 10,187,595 (+)NCBIChiLan1.0ChiLan1.0
IL33
(Pan paniscus - bonobo/pygmy chimpanzee)
Bonobo AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
NHGRI_mPanPan19118,328,274 - 118,370,309 (-)NCBINHGRI_mPanPan1
Mhudiblu_PPA_v096,027,014 - 6,069,540 (+)NCBIMhudiblu_PPA_v0Mhudiblu_PPA_v0panPan3
PanPan1.196,208,479 - 6,250,433 (+)NCBIpanpan1.1PanPan1.1panPan2
PanPan1.1 Ensembl96,234,178 - 6,248,624 (+)Ensemblpanpan1.1panPan2
IL33
(Canis lupus familiaris - dog)
Dog AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
CanFam3.11127,219,878 - 27,256,723 (+)NCBICanFam3.1CanFam3.1canFam3CanFam3.1
CanFam3.1 Ensembl1127,219,878 - 27,256,721 (+)EnsemblCanFam3.1canFam3CanFam3.1
Dog10K_Boxer_Tasha1125,988,860 - 26,025,714 (+)NCBIDog10K_Boxer_Tasha
ROS_Cfam_1.01128,069,676 - 28,106,564 (+)NCBIROS_Cfam_1.0
ROS_Cfam_1.0 Ensembl1128,069,663 - 28,108,194 (+)EnsemblROS_Cfam_1.0 Ensembl
UMICH_Zoey_3.11126,788,250 - 26,825,127 (+)NCBIUMICH_Zoey_3.1
UNSW_CanFamBas_1.01126,610,673 - 26,647,647 (+)NCBIUNSW_CanFamBas_1.0
UU_Cfam_GSD_1.01127,281,817 - 27,318,668 (+)NCBIUU_Cfam_GSD_1.0
Il33
(Ictidomys tridecemlineatus - thirteen-lined ground squirrel)
Squirrel AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
HiC_Itri_2NW_024404947142,170,523 - 142,338,788 (+)NCBIHiC_Itri_2
SpeTri2.0 EnsemblNW_004936539623,248 - 791,470 (+)EnsemblSpeTri2.0SpeTri2.0 Ensembl
SpeTri2.0NW_004936539763,755 - 791,461 (+)NCBISpeTri2.0SpeTri2.0SpeTri2.0
IL33
(Sus scrofa - pig)
Pig AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
Sscrofa11.1 Ensembl1215,899,436 - 215,941,840 (-)EnsemblSscrofa11.1susScr11Sscrofa11.1
Sscrofa11.11215,899,830 - 215,941,944 (-)NCBISscrofa11.1Sscrofa11.1susScr11Sscrofa11.1
Sscrofa10.21241,454,091 - 241,496,130 (-)NCBISscrofa10.2Sscrofa10.2susScr3
IL33
(Chlorocebus sabaeus - green monkey)
Green Monkey AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
ChlSab1.11273,235,585 - 73,283,665 (-)NCBIChlSab1.1ChlSab1.1chlSab2
ChlSab1.1 Ensembl1273,237,406 - 73,252,436 (-)EnsemblChlSab1.1ChlSab1.1 EnsemblchlSab2
Vero_WHO_p1.0NW_02366603861,612,048 - 61,659,928 (-)NCBIVero_WHO_p1.0Vero_WHO_p1.0
Il33
(Heterocephalus glaber - naked mole-rat)
Naked Mole-Rat AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
HetGla_female_1.0 EnsemblNW_00462473610,764,486 - 10,784,864 (+)EnsemblHetGla_female_1.0HetGla_female_1.0 EnsemblhetGla2
HetGla 1.0NW_00462473610,733,944 - 10,786,188 (+)NCBIHetGla_female_1.0HetGla 1.0hetGla2

Variants

.
Variants in Il33
315 total Variants
miRNA Target Status

Predicted Target Of
Summary Value
Count of predictions:391
Count of miRNA genes:217
Interacting mature miRNAs:256
Transcripts:ENSRNOT00000022056
Prediction methods:Microtar, Miranda, Rnahybrid
Result types:miRGate_prediction

The detailed report is available here: Full Report CSV TAB Printer

miRNA Target Status data imported from miRGate (http://mirgate.bioinfo.cnio.es/).
For more information about miRGate, see PMID:25858286 or access the full paper here.


QTLs in Region (mRatBN7.2)
The following QTLs overlap with this region.    Full Report CSV TAB Printer Gviewer
RGD IDSymbolNameLODP ValueTraitSub TraitChrStartStopSpecies
7794788Mcs32Mammary carcinoma susceptibility QTL 322.61mammary gland integrity trait (VT:0010552)mammary tumor incidence/prevalence measurement (CMO:0000946)1115540693238914717Rat
7421630Bp362Blood pressure QTL 3620.001arterial blood pressure trait (VT:2000000)mean arterial blood pressure (CMO:0000009)1118608292241799120Rat
2302378Insul11Insulin level QTL 113.25blood insulin amount (VT:0001560)serum insulin level (CMO:0000358)1144267353251128347Rat
724531Uae5Urinary albumin excretion QTL 54urine albumin amount (VT:0002871)urine albumin level (CMO:0000130)1150700142252085212Rat
1578759Uae30Urinary albumin excretion QTL 303.30.003urine albumin amount (VT:0002871)urine albumin excretion rate (CMO:0000757)1150700247252085048Rat
1578778Pur4Proteinuria QTL 43.30.003urine total protein amount (VT:0000032)urine total protein excretion rate (CMO:0000756)1150700247252085048Rat
1354610Bw34Body weight QTL 344.1body mass (VT:0001259)body weight (CMO:0000012)1151162512256448636Rat
1354646Kidm18Kidney mass QTL 185.7kidney mass (VT:0002707)calculated kidney weight (CMO:0000160)1151162512256448636Rat
1354661Bw33Body weight QTL 335.2body mass (VT:0001259)body weight (CMO:0000012)1151162512256448636Rat
1549837Hcar15Hepatocarcinoma resistance QTL 150.05liver integrity trait (VT:0010547)liver tumorous lesion number (CMO:0001068)1153136852260522016Rat
1354580Scort1Serum corticosterone level QTL 13.4blood corticosterone amount (VT:0005345)blood corticosterone level (CMO:0001172)1156677124256448636Rat
2292220Bp306Blood pressure QTL 3063.470.00087arterial blood pressure trait (VT:2000000)systolic blood pressure (CMO:0000004)1164310393243914901Rat
738032Hcas5Hepatocarcinoma susceptibility QTL 53.12liver integrity trait (VT:0010547)liver tumorous lesion number (CMO:0001068)1176426412257976495Rat
1354624Cm35Cardiac mass QTL355.7heart left ventricle mass (VT:0007031)calculated heart weight (CMO:0000073)1177227632256448636Rat
1354652Kidm20Kidney mass QTL 204.3kidney mass (VT:0002707)calculated kidney weight (CMO:0000160)1177227632256448636Rat
634321Hc1Hypercalciuria QTL 12.91urine calcium amount (VT:0002985)urine calcium excretion rate (CMO:0000763)1178810256240830002Rat
1578763Kidm29Kidney mass QTL 293.30.0001kidney mass (VT:0002707)both kidneys wet weight (CMO:0000085)1179567751260522016Rat
8655655Arrd2Age-related retinal degeneration QTL 27.79retinal layer morphology trait (VT:0003727)percentage of study population developing retinopathy during a period of time (CMO:0002453)1183970203243914901Rat
8655855Arrd3Age-related retinal degeneration QTL 33.07lens clarity trait (VT:0001304)cataract incidence/prevalence measurement (CMO:0001585)1183970203243914901Rat
631838Niddm36Non-insulin dependent diabetes mellitus QTL 360.01insulin secretion trait (VT:0003564)calculated pancreatic islet insulin release measurement (CMO:0001217)1184550676229550676Rat
2312564Glom18Glomerulus QTL 182.40.003kidney glomerulus morphology trait (VT:0005325)index of glomerular damage (CMO:0001135)1185356336231689108Rat
1358898Bp255Blood pressure QTL 2553.6arterial blood pressure trait (VT:2000000)mean arterial blood pressure (CMO:0000009)1191019702246062233Rat
10059590Kidm44Kidney mass QTL 443.420.025kidney mass (VT:0002707)both kidneys wet weight to body weight ratio (CMO:0000340)1191033875236033875Rat
1358191Ept10Estrogen-induced pituitary tumorigenesis QTL 103.8pituitary gland mass (VT:0010496)pituitary gland wet weight (CMO:0000853)1192825253243914732Rat
8552891Epfw5Epididymal fat weight QTL 54.4epididymal fat pad mass (VT:0010421)epididymal fat pad weight to body weight ratio (CMO:0000658)1193113876238113876Rat
1600388Niddm67Non-insulin dependent diabetes mellitus QTL 675.840.000004blood glucose amount (VT:0000188)blood glucose level area under curve (AUC) (CMO:0000350)1195804352257091168Rat
1600395Niddm69Non-insulin dependent diabetes mellitus QTL 694.140.0002blood insulin amount (VT:0001560)plasma insulin level (CMO:0000342)1195804352257091168Rat
1600396Niddm68Non-insulin dependent diabetes mellitus QTL 684.970.0003blood glucose amount (VT:0000188)blood glucose level area under curve (AUC) (CMO:0000350)1195804352257091168Rat
631658Cm7Cardiac mass QTL 75.320.0001aorta mass (VT:0002845)aorta weight (CMO:0000076)1196248093241248093Rat
1358292Cm37Cardiac mass QTL 376.20.00000081heart mass (VT:0007028)heart weight to body weight ratio (CMO:0000074)1196248093241248093Rat
1600374Mcs17Mammary carcinoma susceptibility QTL 173mammary gland integrity trait (VT:0010552)mammary tumor number (CMO:0000343)1197670404242670404Rat
1641926Teswt2Testicular weight QTL 22.82testis mass (VT:1000644)both testes wet weight (CMO:0000175)1197697768238755659Rat
2302375Bw83Body weight QTL 834.870.0002body mass (VT:0001259)body weight (CMO:0000012)1197697768242697768Rat
61376Bp42Blood pressure QTL 4223.4arterial blood pressure trait (VT:2000000)systolic blood pressure (CMO:0000004)1197814409242814409Rat
1298084Thym4Thymus enlargement QTL 410.68thymus mass (VT:0004954)thymus weight to body weight ratio (CMO:0000612)1197814409242814409Rat
1357335Bw39Body weight QTL 393.3body mass (VT:0001259)body weight (CMO:0000012)1197814409242814409Rat
634313Niddm43Non-insulin dependent diabetes mellitus QTL 43blood glucose amount (VT:0000188)blood glucose level (CMO:0000046)1199050459259647894Rat
2293694Bss38Bone structure and strength QTL 387.050.0001femur strength trait (VT:0010010)femur stiffness (CMO:0001674)1201554356246554356Rat
7394701Uae46Urinary albumin excretion QTL 463.60.0056urine albumin amount (VT:0002871)urine albumin excretion rate (CMO:0000757)1201554356246554356Rat
2300175Bmd40Bone mineral density QTL 4015.40.0001femur mineral mass (VT:0010011)bone mineral density (CMO:0001226)1201554356246554356Rat
2293655Bss36Bone structure and strength QTL 3610.660.0001femur strength trait (VT:0010010)femur ultimate force (CMO:0001675)1201554356246554356Rat
2293674Bss39Bone structure and strength QTL 397.10.0001femur strength trait (VT:0010010)femur total energy absorbed before break (CMO:0001677)1201554356246554356Rat
10059587Bw173Body weight QTL 1733.230.025body mass (VT:0001259)body weight (CMO:0000012)1202069611247069611Rat
1600363Hc6Hypercalciuria QTL 62.7urine calcium amount (VT:0002985)urine calcium excretion rate (CMO:0000763)1203995416244113296Rat
1600397Edcs4Endometrial carcinoma susceptibility QTL 42.2uterus morphology trait (VT:0001120)percentage of study population developing endometrioid carcinoma during a period of time (CMO:0001759)1206081677251081677Rat
1357399Bw45Body weight QTL 453.05body mass (VT:0001259)body mass index (BMI) (CMO:0000105)1206329708251329708Rat
1357404Bw42Body weight QTL 424.490.0001body mass (VT:0001259)body weight (CMO:0000012)1206329708251329708Rat
1300168Bp170Blood pressure QTL 1702.76arterial blood pressure trait (VT:2000000)mean arterial blood pressure (CMO:0000009)1207702246228581766Rat
1358916Kidm22Kidney mass QTL 223.32kidney mass (VT:0002707)both kidneys wet weight to body weight ratio (CMO:0000340)1210702053240947965Rat
1358890Bp259Blood pressure QTL 2593.06arterial blood pressure trait (VT:2000000)mean arterial blood pressure (CMO:0000009)1210702053260522016Rat
2292216Bw80Body weight QTL 803.230.0019body mass (VT:0001259)body weight (CMO:0000012)1213533809243914901Rat
724538Kidm1Kidney mass QTL 13.2kidney mass (VT:0002707)calculated kidney weight (CMO:0000160)1213707201252085212Rat
734768Niddm59Non-insulin dependent diabetes mellitus QTL 59body mass (VT:0001259)body weight (CMO:0000012)1213843987258843987Rat
61455Niddm7Non-insulin dependent diabetes mellitus QTL 75.5blood glucose amount (VT:0000188)plasma glucose level (CMO:0000042)1214537555238757011Rat
70211Niddm24Non-insulin dependent diabetes mellitus QTL 243.79blood glucose amount (VT:0000188)blood glucose level area under curve (AUC) (CMO:0000350)1214647894259647894Rat
1549910Bw54Body weight QTL 540.05body mass (VT:0001259)body weight (CMO:0000012)1214647894259647894Rat
61327Eae7Experimental allergic encephalomyelitis QTL 75.6body mass (VT:0001259)change in body weight (CMO:0002045)1216255568260522016Rat
2302040Pia35Pristane induced arthritis QTL 353.80.001blood immunoglobulin amount (VT:0002460)serum immunoglobulin G1 level (CMO:0002115)1216255568260522016Rat
1598821Rf55Renal function QTL 556.3renal blood flow trait (VT:2000006)ratio of change in renal blood flow to change in renal perfusion pressure (CMO:0001239)1218748008257976495Rat
61400Niddm1Non-insulin dependent diabetes mellitus QTL 111blood glucose amount (VT:0000188)blood glucose level (CMO:0000046)1218753689245907899Rat
724533Rf51Renal function QTL 515.30.0002kidney plasma flow trait (VT:0005524)renal plasma flow (CMO:0001914)1218753816256448513Rat
731175Uae20Urinary albumin excretion QTL 203.50.0018urine albumin amount (VT:0002871)urine albumin excretion rate (CMO:0000757)1221264111259647894Rat
10053715Scort24Serum corticosterone level QTL 242.130.0088blood corticosterone amount (VT:0005345)plasma corticosterone level (CMO:0001173)1221414816260522016Rat
724552Glom2Glomerulus QTL 23.30.0001kidney glomerulus morphology trait (VT:0005325)count of superficial glomeruli directly contacting the kidney surface (CMO:0001001)1222363780260522016Rat
1600392Bw123Body weight QTL 1230.001body mass (VT:0001259)body weight (CMO:0000012)1223201027260522016Rat
2293700Bmd27Bone mineral density QTL 276.60.0001femur mineral mass (VT:0010011)trabecular volumetric bone mineral density (CMO:0001729)1224054293243747962Rat
2293701Bmd34Bone mineral density QTL 348.30.0001femur strength trait (VT:0010010)femoral neck ultimate force (CMO:0001703)1224054293243747962Rat
734767Niddm57Non-insulin dependent diabetes mellitus QTL 57body mass (VT:0001259)body weight (CMO:0000012)1224054293260122809Rat
631843Bw116Body weight QTL 1164.10.016abdominal adipose amount (VT:1000220)abdominal fat pad weight (CMO:0000088)1224054293260122809Rat
734769Niddm58Non-insulin dependent diabetes mellitus QTL 58body mass (VT:0001259)body weight (CMO:0000012)1224569538260122809Rat
631215Stl8Serum triglyceride level QTL 89.270.0001blood triglyceride amount (VT:0002644)serum triglyceride level (CMO:0000360)1225126575260522016Rat

Markers in Region
RH127711  
Rat AssemblyChrPosition (strand)SourceJBrowse
mRatBN7.21227,736,156 - 227,736,340 (+)MAPPERmRatBN7.2
Rnor_6.01248,146,813 - 248,146,996NCBIRnor6.0
Rnor_5.01255,397,444 - 255,397,627UniSTSRnor5.0
RGSC_v3.41233,685,581 - 233,685,764UniSTSRGSC3.4
Celera1224,886,301 - 224,886,484UniSTS
RH 3.4 Map11618.51UniSTS
Cytogenetic Map1q52UniSTS
BE110958  
Rat AssemblyChrPosition (strand)SourceJBrowse
mRatBN7.21227,734,650 - 227,734,815 (+)MAPPERmRatBN7.2
Rnor_6.01248,145,307 - 248,145,471NCBIRnor6.0
Rnor_5.01255,395,938 - 255,396,102UniSTSRnor5.0
RGSC_v3.41233,684,075 - 233,684,239UniSTSRGSC3.4
Celera1224,884,795 - 224,884,959UniSTS
RH 3.4 Map11648.4UniSTS
Cytogenetic Map1q52UniSTS
AW533538  
Rat AssemblyChrPosition (strand)SourceJBrowse
mRatBN7.21227,720,881 - 227,721,034 (+)MAPPERmRatBN7.2
Rnor_6.01248,131,537 - 248,131,689NCBIRnor6.0
Rnor_5.01255,382,207 - 255,382,359UniSTSRnor5.0
RGSC_v3.41233,670,248 - 233,670,400UniSTSRGSC3.4
Celera1224,871,054 - 224,871,206UniSTS
RH 3.4 Map11615.7UniSTS
Cytogenetic Map1q52UniSTS


Expression


RNA-SEQ Expression
High: > 1000 TPM value   Medium: Between 11 and 1000 TPM
Low: Between 0.5 and 10 TPM   Below Cutoff: < 0.5 TPM

alimentary part of gastrointestinal system circulatory system endocrine system exocrine system hemolymphoid system hepatobiliary system integumental system musculoskeletal system nervous system renal system reproductive system respiratory system appendage
High
Medium 3 17 32 21 19 21 8 9 47 35 23 11 8
Low 26 25 20 20 2 27 18
Below cutoff

Sequence


Reference Sequences
RefSeq Acc Id: ENSRNOT00000022056   ⟹   ENSRNOP00000022056
Type: CODING
Position:
Rat AssemblyChrPosition (strand)Source
mRatBN7.2 Ensembl1227,721,435 - 227,736,373 (+)Ensembl
Rnor_6.0 Ensembl1248,132,090 - 248,147,029 (+)Ensembl
RefSeq Acc Id: ENSRNOT00000099958   ⟹   ENSRNOP00000076413
Type: CODING
Position:
Rat AssemblyChrPosition (strand)Source
mRatBN7.2 Ensembl1227,729,072 - 227,736,373 (+)Ensembl
RefSeq Acc Id: NM_001014166   ⟹   NP_001014188
RefSeq Status: VALIDATED
Type: CODING
Position:
Rat AssemblyChrPosition (strand)Source
mRatBN7.21227,721,423 - 227,736,374 (+)NCBI
Rnor_6.01248,132,090 - 248,147,030 (+)NCBI
Rnor_5.01255,382,760 - 255,397,661 (+)NCBI
RGSC_v3.41233,670,801 - 233,685,798 (+)RGD
Celera1224,871,607 - 224,886,518 (+)RGD
Sequence:
RefSeq Acc Id: NM_001419498   ⟹   NP_001406427
RefSeq Status: VALIDATED
Type: CODING
Position:
Rat AssemblyChrPosition (strand)Source
mRatBN7.21227,702,048 - 227,736,374 (+)NCBI
RefSeq Acc Id: XM_039084456   ⟹   XP_038940384
Type: CODING
Position:
Rat AssemblyChrPosition (strand)Source
mRatBN7.21227,701,964 - 227,736,374 (+)NCBI
RefSeq Acc Id: XM_039084461   ⟹   XP_038940389
Type: CODING
Position:
Rat AssemblyChrPosition (strand)Source
mRatBN7.21227,723,068 - 227,736,374 (+)NCBI
RefSeq Acc Id: XM_039084466   ⟹   XP_038940394
Type: CODING
Position:
Rat AssemblyChrPosition (strand)Source
mRatBN7.21227,702,007 - 227,736,374 (+)NCBI
RefSeq Acc Id: XM_039084473   ⟹   XP_038940401
Type: CODING
Position:
Rat AssemblyChrPosition (strand)Source
mRatBN7.21227,723,067 - 227,736,374 (+)NCBI
RefSeq Acc Id: XM_039084481   ⟹   XP_038940409
Type: CODING
Position:
Rat AssemblyChrPosition (strand)Source
mRatBN7.21227,717,705 - 227,736,374 (+)NCBI
RefSeq Acc Id: XM_039084491   ⟹   XP_038940419
Type: CODING
Position:
Rat AssemblyChrPosition (strand)Source
mRatBN7.21227,723,083 - 227,736,374 (+)NCBI
Reference Protein Sequences
RefSeq Acc Id: NP_001014188   ⟸   NM_001014166
- UniProtKB: Q66H70 (UniProtKB/Swiss-Prot),   A6I0X6 (UniProtKB/TrEMBL),   A0A096MIT4 (UniProtKB/TrEMBL)
- Sequence:
RefSeq Acc Id: ENSRNOP00000022056   ⟸   ENSRNOT00000022056
RefSeq Acc Id: XP_038940384   ⟸   XM_039084456
- Peptide Label: isoform X1
- UniProtKB: A0A096MIT4 (UniProtKB/TrEMBL)
RefSeq Acc Id: XP_038940394   ⟸   XM_039084466
- Peptide Label: isoform X1
- UniProtKB: A0A096MIT4 (UniProtKB/TrEMBL)
RefSeq Acc Id: XP_038940409   ⟸   XM_039084481
- Peptide Label: isoform X1
- UniProtKB: A0A096MIT4 (UniProtKB/TrEMBL)
RefSeq Acc Id: XP_038940401   ⟸   XM_039084473
- Peptide Label: isoform X1
- UniProtKB: A0A096MIT4 (UniProtKB/TrEMBL)
RefSeq Acc Id: XP_038940389   ⟸   XM_039084461
- Peptide Label: isoform X1
- UniProtKB: A0A096MIT4 (UniProtKB/TrEMBL)
RefSeq Acc Id: XP_038940419   ⟸   XM_039084491
- Peptide Label: isoform X2
- UniProtKB: Q66H70 (UniProtKB/Swiss-Prot),   A6I0X6 (UniProtKB/TrEMBL),   A0A096MIT4 (UniProtKB/TrEMBL)
RefSeq Acc Id: ENSRNOP00000076413   ⟸   ENSRNOT00000099958
RefSeq Acc Id: NP_001406427   ⟸   NM_001419498
- UniProtKB: Q66H70 (UniProtKB/Swiss-Prot),   A6I0X6 (UniProtKB/TrEMBL),   A0A096MIT4 (UniProtKB/TrEMBL)

Protein Structures
Name Modeler Protein Id AA Range Protein Structure
AF-Q66H70-F1-model_v2 AlphaFold Q66H70 1-264 view protein structure

Transcriptome

eQTL   View at Phenogen
WGCNA   View at Phenogen
Tissue/Strain Expression   View at Phenogen

Promoters
RGD ID:13690849
Promoter ID:EPDNEW_R1374
Type:single initiation site
Name:Il33_1
Description:interleukin 33
SO ACC ID:SO:0000170
Source:EPDNEW (Eukaryotic Promoter Database, http://epd.vital-it.ch/)
Experiment Methods:Single-end sequencing.
Position:
Rat AssemblyChrPosition (strand)Source
Rnor_6.01248,132,078 - 248,132,138EPDNEW

Additional Information

Database Acc Id Source(s)
AGR Gene RGD:1311155 AgrOrtholog
BioCyc Gene G2FUF-55951 BioCyc
Ensembl Genes ENSRNOG00000016456 Ensembl, ENTREZGENE, UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
Ensembl Transcript ENSRNOT00000022056 ENTREZGENE, UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  ENSRNOT00000099958.1 UniProtKB/TrEMBL
Gene3D-CATH 2.80.10.50 UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
IMAGE_CLONE IMAGE:7130307 IMAGE-MGC_LOAD
InterPro IL-33 UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
KEGG Report rno:361749 UniProtKB/Swiss-Prot
MGC_CLONE MGC:94210 IMAGE-MGC_LOAD
NCBI Gene 361749 ENTREZGENE
PANTHER INTERLEUKIN-33 UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  PTHR21114 UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
Pfam IL33 UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
PhenoGen Il33 PhenoGen
RatGTEx ENSRNOG00000016456 RatGTEx
UniProt A0A096MIT4 ENTREZGENE, UniProtKB/TrEMBL
  A0A8I5Y068_RAT UniProtKB/TrEMBL
  A6I0X6 ENTREZGENE, UniProtKB/TrEMBL
  IL33_RAT UniProtKB/Swiss-Prot, ENTREZGENE


Nomenclature History
Date Current Symbol Current Name Previous Symbol Previous Name Description Reference Status
2008-02-27 Il33  interleukin 33  RGD1311155  similar to RIKEN cDNA 9230117N10  Nomenclature updated to reflect human and mouse nomenclature 1299863 APPROVED
2005-12-06 RGD1311155  similar to RIKEN cDNA 9230117N10  RGD1311155_predicted  similar to RIKEN cDNA 9230117N10 (predicted)  Symbol and Name updated 1559027 APPROVED
2005-01-20 RGD1311155_predicted  similar to RIKEN cDNA 9230117N10 (predicted)  LOC361749_predicted    Symbol and Name status set to approved 1331353 APPROVED
2005-01-12 LOC361749_predicted  similar to RIKEN cDNA 9230117N10 (predicted)      Symbol and Name status set to provisional 70820 PROVISIONAL